Trump announces trade deal with EU following months of negotiations
RICHMOND, Va. - Owens & Minor Inc . (NYSE:OMI) reported first-quarter earnings that exceeded analyst expectations, while reaffirming its full-year 2025 guidance on Thursday.
The healthcare solutions company’s shares rose 3.09% in premarket trading following the announcement.
Owens & Minor posted adjusted earnings per share of $0.23 for Q1 2025, surpassing the analyst consensus of $0.20. Revenue came in at $2.63 billion, slightly below estimates of $2.66 billion but up 0.7% YoY.
The company’s Patient Direct segment led growth, with revenue increasing 5.7% YoY to $673.9 million. Operating margin for the segment expanded 173 basis points to 8.92%.
"Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies," said Edward A. Pesicka, President & CEO of Owens & Minor. "The top-line growth combined with strong operational execution delivered mid-teen expansion in EBITDA for the segment."
For the full year 2025, Owens & Minor reaffirmed its outlook, projecting adjusted EPS of $1.60-$1.85 and revenue of $10.85-$11.15 billion. The midpoint of both ranges aligns closely with current analyst expectations.
The company also noted it remains "actively engaged" in the potential sale of its Products & Healthcare Services (NASDAQ:HCSG) segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.